Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Completion Rate
    0%(0/1)
    Active Trials
    0(0%)
    Terminated
    1(100%)

    Phase Distribution

    Phase 2
    1
    100%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution1 total trials
    Phase 2Efficacy & side effects
    1(100.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 1 finished

    Non-Completion Rate

    100.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    1

    all time

    Status Distribution
    Terminated(1)

    Detailed Status

    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    1
    Active
    0
    Success Rate
    0.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 21 (100.0%)

    Trials by Status

    terminated1100%

    Recent Activity

    0 active trials
    Showing 1 of 1
    terminatedphase_2

    R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma

    NCT00788606

    Clinical Trials (1)

    Showing 1 of 1 trials
    NCT00788606Phase 2

    R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma

    Terminated

    All 1 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    1